CL2008000170A1 - Sal estroncica de atorvastatina, o sus hidratos o polimorfos; metodo de preparacion; composicion farmaceutica, util para la prevencion o tratamiento de hiperlipidemia e hipercolesterolemia. - Google Patents
Sal estroncica de atorvastatina, o sus hidratos o polimorfos; metodo de preparacion; composicion farmaceutica, util para la prevencion o tratamiento de hiperlipidemia e hipercolesterolemia.Info
- Publication number
- CL2008000170A1 CL2008000170A1 CL200800170A CL2008000170A CL2008000170A1 CL 2008000170 A1 CL2008000170 A1 CL 2008000170A1 CL 200800170 A CL200800170 A CL 200800170A CL 2008000170 A CL2008000170 A CL 2008000170A CL 2008000170 A1 CL2008000170 A1 CL 2008000170A1
- Authority
- CL
- Chile
- Prior art keywords
- strontique
- hydrats
- polymorphes
- atorvastatin
- hypercholesterolemia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070008896A KR100878140B1 (ko) | 2007-01-29 | 2007-01-29 | 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2008000170A1 true CL2008000170A1 (es) | 2008-05-23 |
Family
ID=39674220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL200800170A CL2008000170A1 (es) | 2007-01-29 | 2008-01-21 | Sal estroncica de atorvastatina, o sus hidratos o polimorfos; metodo de preparacion; composicion farmaceutica, util para la prevencion o tratamiento de hiperlipidemia e hipercolesterolemia. |
Country Status (16)
Country | Link |
---|---|
US (1) | US20100120888A1 (es) |
EP (1) | EP2121596A4 (es) |
JP (1) | JP2010516756A (es) |
KR (1) | KR100878140B1 (es) |
CN (1) | CN101600688A (es) |
AR (1) | AR065070A1 (es) |
AU (1) | AU2008211906B2 (es) |
BR (1) | BRPI0808369A2 (es) |
CA (1) | CA2675996A1 (es) |
CL (1) | CL2008000170A1 (es) |
IL (1) | IL200069A0 (es) |
MX (1) | MX2009007922A (es) |
NZ (1) | NZ579339A (es) |
PE (1) | PE20081722A1 (es) |
TW (1) | TW200844093A (es) |
WO (1) | WO2008093951A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101973922B (zh) * | 2009-05-27 | 2013-01-23 | 天津和美生物技术有限公司 | 阿伐他汀半锶盐多晶型物、其制备和作为HMG-CoA酶抑制剂的应用 |
KR20120011249A (ko) | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
IN2014DN06942A (es) * | 2012-01-20 | 2015-04-10 | Lianyungang Jinkang Hexin Pharmaceutical Co Ltd | |
CN102935076A (zh) * | 2012-11-29 | 2013-02-20 | 康普药业股份有限公司 | 一种含阿托伐他汀钠的胶囊及其制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
SI0848705T1 (en) * | 1995-07-17 | 2002-04-30 | Warner-Lambert Company | Crystalline r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
UA74075C2 (en) | 2001-06-29 | 2005-10-17 | Warner Lambert Co | NOVEL CRYSTALLINE FORMS [R-(R*,R*)]-2-(4-FLUOROPHENYL)-b, d-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1??-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1)(ATORVASTATIN) (VARIANTS) |
EP1744770A2 (en) * | 2004-05-06 | 2007-01-24 | Osteologix A/S | High yield and rapid syntheses methods for producing metallo-organic salts |
CA2570389A1 (en) * | 2004-06-17 | 2005-12-29 | Osteologix A/S | Treatments comprising strontium for rheumatic and arthritic diseases and pain |
-
2007
- 2007-01-29 KR KR1020070008896A patent/KR100878140B1/ko active IP Right Grant
-
2008
- 2008-01-21 BR BRPI0808369-0A patent/BRPI0808369A2/pt not_active IP Right Cessation
- 2008-01-21 WO PCT/KR2008/000357 patent/WO2008093951A1/en active Application Filing
- 2008-01-21 EP EP08704884A patent/EP2121596A4/en not_active Withdrawn
- 2008-01-21 JP JP2009547168A patent/JP2010516756A/ja not_active Withdrawn
- 2008-01-21 US US12/524,807 patent/US20100120888A1/en not_active Abandoned
- 2008-01-21 NZ NZ579339A patent/NZ579339A/en unknown
- 2008-01-21 AU AU2008211906A patent/AU2008211906B2/en not_active Expired - Fee Related
- 2008-01-21 CA CA002675996A patent/CA2675996A1/en not_active Abandoned
- 2008-01-21 MX MX2009007922A patent/MX2009007922A/es not_active Application Discontinuation
- 2008-01-21 CN CNA2008800034354A patent/CN101600688A/zh active Pending
- 2008-01-21 CL CL200800170A patent/CL2008000170A1/es unknown
- 2008-01-28 PE PE2008000205A patent/PE20081722A1/es not_active Application Discontinuation
- 2008-01-28 TW TW097103064A patent/TW200844093A/zh unknown
- 2008-01-29 AR ARP080100349A patent/AR065070A1/es not_active Application Discontinuation
-
2009
- 2009-07-26 IL IL200069A patent/IL200069A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
PE20081722A1 (es) | 2009-01-22 |
KR20080070951A (ko) | 2008-08-01 |
EP2121596A4 (en) | 2010-03-17 |
IL200069A0 (en) | 2010-04-15 |
TW200844093A (en) | 2008-11-16 |
KR100878140B1 (ko) | 2009-01-12 |
BRPI0808369A2 (pt) | 2014-08-19 |
JP2010516756A (ja) | 2010-05-20 |
CN101600688A (zh) | 2009-12-09 |
US20100120888A1 (en) | 2010-05-13 |
CA2675996A1 (en) | 2008-08-07 |
WO2008093951A1 (en) | 2008-08-07 |
MX2009007922A (es) | 2009-08-07 |
AU2008211906B2 (en) | 2010-11-18 |
AR065070A1 (es) | 2009-05-13 |
AU2008211906A1 (en) | 2008-08-07 |
EP2121596A1 (en) | 2009-11-25 |
NZ579339A (en) | 2011-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0909768A2 (pt) | composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto | |
BRPI0818244A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença | |
BRPI1013763A2 (pt) | Composto ou sal do mesmo, prodroga, composição farmacêutica, agente diminuidor da proteína de ligação de retinol 4, agente para a profilaxia ou tratamento de diabetes, e, uso de um composto | |
BRPI0610514A2 (pt) | composto, composição farmacêutica, e, método de tratamento de um distúrbio | |
BRPI0817525A2 (pt) | Composto, composição farmacêutica, e, metódo de tratamento, controle ou prevenção de uma doença ou distúrbio. | |
BR112012003464A2 (pt) | composto, composição farmacêutica, usos de uma composição farmacêutica e de um composto, e, método para tratar uma doença ou um distúrbio." | |
BRPI0810246A2 (pt) | Inibidores da dpp-iv incluindo o grupo beta-amino, método de preparação do mesmo e composição farmacêutica contendo o mesmo para prevenção e tratamento da diabetes ou obesidade. | |
BRPI0716696A2 (pt) | Sistema de aplicação para tratamento remoto de um animal | |
CL2007002650A1 (es) | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. | |
CL2007003049A1 (es) | Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos. | |
BRPI0820665A2 (pt) | compostos de peptidil nitrilas, processos para fabricação dos mesmos, composição farmacêutica, combinação e uso de ditos compostos | |
BR112012004333A2 (pt) | composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio. | |
BRPI0815591A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio. | |
CL2007001882A1 (es) | Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos. | |
CL2007002686A1 (es) | Compuestos derivados de 2h-isoquinolin-1-ona y 3h-quinazolin-4-ona, inhibidores de cinasa rho; y composicion farmaceutica, util para el tratamiento de una enfermedad o afeccion cardiovascular. | |
BRPI0813001A2 (pt) | composto, método de tratamento ou profilaxia de dor neuropática e composição farmacêutica | |
BRPI0810354A2 (pt) | Composto, uso de um composto, composição farmacêutica, e, método de tratamento de um dispositivo de dor | |
CL2007003758A1 (es) | Compuestos derivados de aminopirimidina, inhibidores de plk1; composicion farmaceutica, util para el tratamiento de cancer. | |
CL2007003423A1 (es) | Compuestos derivados de pirimidinas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis reumatoidea, aterosclerosis, entre otras enfermeda | |
CL2007001881A1 (es) | Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos. | |
CL2007002920A1 (es) | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. | |
CL2008000887A1 (es) | Compuestos derivados de 3-hidroxi-1h-pirimidin-4-ona o 3-hidroxi-piran-4-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad neurodegenerativa causada por la presencia de | |
BRPI0907977A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
BRPI0907974A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
BRPI0923856A2 (pt) | composto, composição farmacêutica, uso de um composto, e método para tratar uma doença ou distúrbio. |